BayPine LP announced on April 14 that it has entered into a definitive agreement to acquire CenExel Clinical Research, Inc. in Salt Lake City, Utah. Following the closing of the transaction, BayPine will be the majority investor in CenExel alongside previous private equity investor Webster Equity Partners, which will retain a minority stake, as well as CenExel management.
CenExel Clinical Research provides medical and scientific support in the design and execution of clinical trials. Formed in 2018, CenExel works with trial sponsors and contract research organizations to reduce costs and development times for therapies.
BayPine is a private investment firm that drives innovation, digital transformation, and sustainable growth in market-leading businesses across core sectors of the economy. The company is headquartered in Boston, Massachusetts, with an additional office in New York.
The transaction is subject to customary closing conditions and regulatory approvals and is expected to be completed during the second quarter of 2025. Terms of the transaction were not disclosed.
According to data in the LevinPro HC database, this transaction represents the fifth clinical trial acquisition of 2025. Other acquirers in the specialty this year include Pratia, Flourish Research, Clario and The START Center for Cancer Research. There were 27 clinical trial transactions announced in 2024, and 42 announced in 2023.
